A transplant-ICU medication curriculum centered on the tension between rejection, infection and drug toxicity. It teaches how to interpret calcineurin-inhibitor levels, interactions, AKI and cytopenias without making the dangerous assumption that all immunosuppression should either be continued unchanged or stopped completely.
Differentiate calcineurin-inhibitor nephrotoxicity from rejection and other causes of graft dysfunction.
Recognize major CYP3A interactions that can rapidly change tacrolimus/cyclosporine exposure.
Adjust antimetabolite immunosuppression thoughtfully during severe infection/cytopenia with transplant-team input.
Use trough concentrations as one clinical data stream—not as the diagnosis by themselves.
Connect immunosuppression decisions with opportunistic-infection prophylaxis and transplant-specific organ physiology.
Graft dysfunction, rejection, infection and hemodynamics.
Early graft function, vascular complications and immunosuppression.
The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.
ICU role: Calcineurin-inhibitor backbone for many solid-organ transplants.
Monitor: Trough, creatinine/urine output, K/Mg, neuro status, interaction changes.
ICU role: Alternative calcineurin inhibitor in kidney/liver/heart transplant regimens.
Monitor: Concentration, creatinine, K/Mg, BP, liver tests.
ICU role: Antimetabolite used with calcineurin inhibitor/steroid regimens.
Monitor: CBC, infection, GI tolerance, renal/liver function.
ICU role: High-potency glucocorticoid often used in rejection treatment and peri-transplant protocols.
Monitor: Glucose, infection, response and biopsy/graft data.
ICU role: Stress-dose glucocorticoid for adrenal/shock physiology, not a replacement for transplant rejection regimens.
Monitor: Hemodynamics, glucose, infection and total steroid exposure.
ICU role: IV anti-CMV therapy/prophylaxis drug for high-risk transplant CMV disease contexts.
Monitor: CBC, renal function, CMV viral response.
ICU role: HSV/VZV treatment/prophylaxis in immunocompromised patients.
Monitor: Creatinine, neuro status, hydration.
ICU role: Pneumocystis and selected opportunistic-infection prophylaxis/treatment.
Monitor: K, creatinine, CBC.
ICU role: Mold-active azole for selected invasive aspergillosis and fungal disease.
Monitor: Azole TDM when indicated, liver tests, QT and calcineurin-inhibitor troughs.
| Agent | ICU role | Why I choose it | Why I hesitate | What I monitor |
|---|---|---|---|---|
| Tacrolimus Calcineurin Inhibitor Immunosuppressant | Calcineurin-inhibitor backbone for many solid-organ transplants. | ✓ Powerful maintenance immunosuppression with trough-guided titration. | ✕ AKI, hyperkalemia, tremor/seizures/PRES and major CYP3A interaction liability. | Trough, creatinine/urine output, K/Mg, neuro status, interaction changes. |
| Cyclosporine (Modified) Calcineurin Inhibitor Immunosuppressant | Alternative calcineurin inhibitor in kidney/liver/heart transplant regimens. | ✓ Established option when program-specific regimen uses cyclosporine. | ✕ Nephrotoxicity, hypertension, neurotoxicity and formulation non-interchangeability. | Concentration, creatinine, K/Mg, BP, liver tests. |
| Mycophenolate Mofetil (MMF) Antimetabolite Immunosuppressant / Inosine Monophosphate Dehydrogenase Inhibitor | Antimetabolite used with calcineurin inhibitor/steroid regimens. | ✓ Provides synergistic maintenance immunosuppression without calcineurin nephrotoxicity. | ✕ Neutropenia, GI toxicity, severe infection and major embryo-fetal toxicity. | CBC, infection, GI tolerance, renal/liver function. |
| Methylprednisolone Intermediate-Acting Synthetic Glucocorticoid with Minimal Mineralocorticoid Activity | High-potency glucocorticoid often used in rejection treatment and peri-transplant protocols. | ✓ Useful for transplant-program steroid pulses when acute cellular rejection is diagnosed/suspected appropriately. | ✕ Infection, hyperglycemia, delirium and myopathy; do not pulse blindly for every graft dysfunction. | Glucose, infection, response and biopsy/graft data. |
| Hydrocortisone Short-Acting Glucocorticoid with Clinically Relevant Mineralocorticoid Activity | Stress-dose glucocorticoid for adrenal/shock physiology, not a replacement for transplant rejection regimens. | ✓ Use when the ICU indication is septic shock/adrenal crisis and coordinate with baseline transplant steroids. | ✕ Do not assume stress-dose hydrocortisone alone provides adequate rejection treatment. | Hemodynamics, glucose, infection and total steroid exposure. |
| Ganciclovir Antiviral nucleoside analogue | IV anti-CMV therapy/prophylaxis drug for high-risk transplant CMV disease contexts. | ✓ Severe or tissue-invasive CMV when IV therapy is indicated. | ✕ Marrow suppression plus renal-dose complexity; can compound MMF cytopenias. | CBC, renal function, CMV viral response. |
| Acyclovir Antiviral nucleoside analogue | HSV/VZV treatment/prophylaxis in immunocompromised patients. | ✓ Appropriate herpesvirus syndrome with adequate hydration/renal adjustment. | ✕ Crystal nephropathy and neurotoxicity in renal dysfunction. | Creatinine, neuro status, hydration. |
| Trimethoprim–Sulfamethoxazole (TMP-SMX) Sulfonamide & Folate Antagonist Combination | Pneumocystis and selected opportunistic-infection prophylaxis/treatment. | ✓ High-value transplant prophylaxis when tolerated. | ✕ Hyperkalemia, creatinine rise and marrow suppression can mimic/worsen calcineurin/MMF toxicity. | K, creatinine, CBC. |
| Voriconazole Triazole antifungal | Mold-active azole for selected invasive aspergillosis and fungal disease. | ✓ Use when the fungal syndrome/susceptibility fits. | ✕ Potent CYP3A interaction can sharply increase tacrolimus/cyclosporine exposure; hepatic/neuro/QT toxicity. | Azole TDM when indicated, liver tests, QT and calcineurin-inhibitor troughs. |
Why: Calcineurin-inhibitor toxicity and rejection can look similar and can coexist.
Why: Severe infection and cytopenia change the risk balance, but abrupt total withdrawal can also be harmful.
Why: Neurotoxicity is exposure- and physiology-dependent and requires cause-directed drug management.
Why: Escalating immunosuppression into untreated invasive infection can be catastrophic.
Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.
Stable kidney transplant recipient is admitted and home tacrolimus is continued.
Confirm exact formulation/dose/timing and obtain the appropriate trough target from the transplant plan rather than using a generic therapeutic range.
Voriconazole is started for suspected invasive aspergillosis in a tacrolimus-treated patient.
Anticipate a major CYP3A interaction before toxicity occurs: coordinate tacrolimus dose reduction/holding and frequent trough monitoring.
Septic transplant recipient on MMF has ANC 350/µL.
Treat infection, review all marrow-toxic drugs and coordinate temporary MMF reduction/holding rather than continuing unchanged by default.
Kidney transplant creatinine doubles; tacrolimus trough is high and Doppler is normal, but there is new donor-specific antibody concern.
Do not choose a single diagnosis prematurely. Reduce toxic exposure while obtaining transplant-specific rejection assessment/biopsy if indicated; toxicity and rejection can coexist.
Liver transplant patient has worsening LFTs, shock, CMV viremia and possible acute cellular rejection.
Run parallel graft/infection pathways: stabilize/treat infection, obtain graft-directed diagnostics and coordinate the minimum safe immunosuppression plus any rejection therapy with transplant hepatology/ID rather than reflex pulse steroids or total withdrawal.
Potent calcineurin inhibitor central to many solid-organ transplant regimens. ICU management requires trough-guided dosing, meticulous CYP3A interaction review, and differentiation of rejection from tacrolimus nephro/neurotoxicit…
Calcineurin inhibitor used in solid-organ transplantation with major nephrotoxicity, hypertension and CYP3A/P-glycoprotein interaction risks; modified and non-modified formulations are not interchangeable without careful monitori…
Antimetabolite maintenance immunosuppressant used with other agents after solid-organ transplantation. ICU decisions center on cytopenias, severe infection, GI intolerance, renal dysfunction and its major embryo-fetal toxicity.
Potent parenteral glucocorticoid with ~5× the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid action — cornerstone therapy for severe asthma and COPD exacerbations, and non-resolving fibroproliferative A…
Short-acting glucocorticoid with mineralocorticoid activity used in acute adrenal crisis and commonly used when corticosteroids are chosen for adult septic shock; current guidelines support corticosteroids in septic shock but do …
IV anti-CMV drug for severe CMV disease in immunocompromised hosts; major toxicities are marrow suppression and renal accumulation.
IV antiviral essential for HSV encephalitis/disseminated HSV and severe VZV; renal dose adjustment and crystalluria/neurotoxicity are central ICU issues.
Sequential folate pathway inhibitor used for Pneumocystis jirovecii pneumonia (PJP), selected susceptible bacterial infections, Nocardia, and as an active option for Stenotrophomonas maltophilia. Doses are conventionally expresse…
Preferred primary therapy for invasive aspergillosis with nonlinear pharmacokinetics, major interactions and a strong role for TDM.
This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.